Cost-effectiveness of simvastatin in the secondary prevention of coronary artery disease in Canada

Riviere, Marc; Wang, Shanshan
April 1997
CMAJ: Canadian Medical Association Journal;04/01/97, Vol. 156 Issue 7, p991
Academic Journal
Determines the cost-effectiveness of simvastatin in the secondary prevention of coronary artery disease (CAD) in Canada. Outcome measures of the study; Reduced mortality and morbidity among patients given simvastatin compared to control subjects; Suggestion that simvastatin provides a cost-effective approach to long-term prevention of secondary CAD in Canada.


Related Articles

  • Many CAD patients referred for invasive intervention are on suboptimal medical therapy.  // Modern Medicine;May96, Vol. 64 Issue 5, p30 

    Reports on the suboptimal chemotherapy of patients with coronary artery disease (CAD). Safety of using suboptimal medical therapy instead of invasive interventions.

  • Increased drug therapy may be all that CAD patients need.  // Geriatrics;May96, Vol. 51 Issue 5, p56 

    Reports on treatment of people with coronary artery disease. Effectiveness of increased medications.

  • Fix for furry arteries. Coghlan, Andy // New Scientist;11/15/97, Vol. 156 Issue 2108, p6 

    Highlights research on drugs for tackling the root cause of blockages in coronary arteries. Suppression of levels of cholesterol; Disruption of endothelial inflammation; Prevention of activation of genes in endothelial cells that amplify inflammation.

  • Combo therapy for 2° CHD prevention not uniform in the US.  // PharmacoEconomics & Outcomes News;2/20/2010, Issue 597, p6 

    The article discusses research by J. Tija et al published in the January 2010 issue of the journal of "Drugs and Aging" on the effectivity of combination drug therapy for the secondary prevention of coronary heart disease (CHD) in the U.S. and the subpopulation in danger of underusing the therapy.

  • Lipid-lowering therapy after coronary artery bypass grafting: Time for more aggressive intervention. Lucas Jr., B. Daniel // American Journal of Health-System Pharmacy;11/1/2002, Vol. 59 Issue 21, p2101 

    Reflects the approach of health care providers toward lipid management in the patient with coronary heart disease (CHD). Comparison between primary and secondary prevention of CHD; Evaluation of the lipid-lowering therapy ; Attempts to enhance medical compliance and reduce cholesterol levels.

  • AFFAIRS OF THE HEART. Karpa, Kelly Dowhower // Drug Topics;10/20/2003, Vol. 147 Issue 20, pHSE11 

    Proposes the use of cocktail drugs to treat acute coronary syndrome. Role of pharmacists; Function of beta-blockers; Function of antiplatelet/anticoagulation drugs; Lipid-lowering medications.

  • A CASE REPORT OF 5-FLUOROURACIL-INDUCED CORONARY ARTERY VASOSPASM. Connolly, Suzanne; Scott, Peter; Cochrane, L. David; Harte, Robert // Ulster Medical Journal;2010, Vol. 79 Issue 3, p135 

    A letter to the editor is presented that describes the case of a 76-year-old man diagnosed with coronary artery vasopasm induced by the chemotherapeutic agent 5-Flurouracil.

  • Lowering LDL Cholesterol Levels Benefits Patients with Heart Disease. Rose, Verna L. // American Family Physician;8/1/1999, Vol. 60 Issue 2, p600 

    Provides information on the results from the Atorvastatin Versus Revascularization Treatments trial focusing of the effectiveness of atorvastatin in patients with stable coronary artery disease. Methodology; Conclusions; Implications.

  • Pravastatin/cholestyramine combination is more cost-effective than monotherapy.  // Modern Medicine;Jan98, Vol. 66 Issue 1, p21 

    Discusses the abstract of the article `Pravastatin alone and in combination with low cholestyramine in patients with primary hypercholesterolemia and coronary artery disease,' by M.K. Ito and R. Shabetai, which appeared in the September 15, 1997 issue of `American Journal of Cardiology.'


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics